Drug Trial Radar · NCT05952986
A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Jan 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
22
Actual
Start
May 3, 2023
Primary completion
Mar 26, 2024
Study completion Mar 26, 2024
Sponsor
- Lead sponsor
- Oneness Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, placebo-controlled, and double-blind study to evaluate the safety and bridging PK profile of FB825 for single SC administration in healthy adults.
Conditions
- Atopic Dermatitis
Interventions
FB825 or Placebo in subcutaneous routeDrug
FB825 or placebo solution for SC injection
FB825 in intravenous routeDrug
FB825 solution for IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventTime frame: 24 months
- AUC0-infTime frame: 19 months
- AUC0-tTime frame: 19 months
- CmaxTime frame: 19 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Phase I center
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.